曲伏前列素滴眼液对青光眼的疗效及基础泪液分泌量的影响

Efficacy of travoprost eye drops in treatment of glaucoma and its effect on schirmer Ⅰ test

目的:探讨曲伏前列素滴眼液对青光眼的疗效及基础泪液分泌量(schirmerⅠtest,SIt)的影响。方法:选择在我院治疗的原发性开角型青光眼患者101例(142眼),采用曲伏前列素滴眼液治疗,观察治疗效果以及患者视力、散光度、眼压及SIt变化情况。结果:142眼中显效96眼(67.61%),有效36眼(25.35%),无效10眼(7.04%),总有效率为92.96%。与治疗前比较,治疗后患者视力明显提高,散光度明显降低(均P<0.05),治疗后3个月视力和散光度分别为(0.84±0.19)和(1.15±0.81)D;眼压也明显降低(P<0.05);治疗后4周与治疗后8周的眼压比较,差异无统计学意义(P>0.05);治疗后SIt明显减少(P<0.05),其中治疗后3个月SIt最少,为(5.98±1.26)mm·(5 min)^(-1)。治疗期间不良反应发生率为18.31%,未出现严重不良反应。结论:曲伏前列素滴眼液治疗原发性开角型青光眼有较好的疗效,安全性较高,但会引起患者泪液分泌减少。

Objective： To investigate the efficacy of travoprost eye drops in treatment of glaucoma and its effect on schirmer Ⅰ test（Sit）. Methods： One hundred and one cases （142 eyes） of primary openangle glaucoma in our hospital were treated with travoprost eye drops, the therapeutic effect and the changes of visual acuity, astigmatism, intraocular pressure and Sit were observed. Results： Among the 142 eyes, 96 eyes （67.61%） were markedly effective, 36 eyes （25. 35% ） were effective, 10 eyes （7. 04% ） were invalid, the total effective rate was 92.96%. After treatment the visual acuity was significantly improved and the astigmatism was significantly lower than before treatment （all P 〈 0.05 ）. The visual acuity and astigmatism degree were （0.84 ± 0.19） and （1.15 ± 0.81 ） D 3 months after treatment; the intraocular pressure difference was not statistically significant between 4 and 8 weeks treatment （ P 〉 0.05 ）. After treatment Sit was significantly lower than before treatment （ P 〈 0.05 ）, which was least at 3 months after treatment[ （5.98 ± 1.26） mm· （5 min）^-1]. The incidence of adverse reactions was 18.31%, and no serious adverse reactions occurred during the treatment. Conclusion： Travoprost eye drops has a good effect in treatment of primary openangle glaucoma and high safety, but it can cause lacrimal secretion decreased.